| Title |
Dabrafenib and its potential for the treatment of metastatic melanoma
|
|---|---|
| Published in |
Drug Design, Development and Therapy, December 2012
|
| DOI | 10.2147/dddt.s38998 |
| Pubmed ID | |
| Authors |
Alexander M Menzies, Georgina V Long, Rajmohan Murali |
| Abstract |
The purpose of this study is to review the development of BRAF inhibitors, with emphasis on the trials conducted with dabrafenib (GSK2118436) and the evolving role of dabrafenib in treatment for melanoma patients. Fifty percent of cutaneous melanomas have mutations in BRAF, resulting in elevated activity of the mitogen-activated protein kinase signaling pathway. Dabrafenib inhibits the mutant BRAF (BRAF(mut)) protein in melanomas with BRAF(V600E) and BRAF(V600K) genotypes. BRAF(V600E) metastatic melanoma patients who receive dabrafenib treatment exhibit high clinical response rates and compared with dacarbazine chemotherapy, progression-free survival. Efficacy has also been demonstrated in BRAF(V600K) patients and in those with brain metastases. Dabrafenib has a generally mild and manageable toxicity profile. Cutaneous squamous cell carcinomas and pyrexia are the most significant adverse effects. Dabrafenib appears similar to vemurafenib with regard to efficacy but it is associated with less toxicity. It is expected that new combinations of targeted drugs, such as the combination of dabrafenib and trametinib (GSK1120212, a MEK inhibitor), will provide higher response rates and more durable clinical benefit than dabrafenib monotherapy. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 234 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Ecuador | 1 | <1% |
| Germany | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 230 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 43 | 18% |
| Researcher | 38 | 16% |
| Student > Ph. D. Student | 36 | 15% |
| Student > Master | 24 | 10% |
| Other | 15 | 6% |
| Other | 24 | 10% |
| Unknown | 54 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 21% |
| Agricultural and Biological Sciences | 45 | 19% |
| Biochemistry, Genetics and Molecular Biology | 38 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 8% |
| Chemistry | 5 | 2% |
| Other | 25 | 11% |
| Unknown | 54 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#4,768,330
of 25,806,763 outputs
Outputs from Drug Design, Development and Therapy
#288
of 2,283 outputs
Outputs of similar age
#44,748
of 288,039 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 13 outputs
Altmetric has tracked 25,806,763 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,283 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 288,039 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.